# KalVista Pharmaceuticals, Inc. (KALV) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/KALV
## Company Profile
- Ticker: KALV
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United Kingdom
## Stock Data
- Close: 26.95 USD
- Market cap: 1434309522.72 USD
- Last updated: 2026-06-03
## Business Overview
### Hereditary Angioedema Company
KalVista Pharmaceuticals develops and commercializes therapies for hereditary angioedema. Its lead franchise is based on oral inhibition of plasma kallikrein during acute attacks.
### EKTERLY
EKTERLY, or sebetralstat, is the first approved oral on-demand treatment for hereditary angioedema attacks. It is approved in multiple countries for patients age 12 and older and is commercialized directly or through regional partners.
### Pediatric Expansion
The Phase 3 KONFIDENT-KID trial has completed enrollment in children ages 2–11. KalVista plans to use the study to extend oral on-demand treatment to younger patients and pursue additional global filings.
## Why The Stock Is Moving

Current closing-price context is not available for KALV.

## Future Catalysts

- U.S. NDA filing for EKTERLY in children ages 2–11 planned for the third quarter of 2026.
- Potential U.S. pediatric launch anticipated in 2027, subject to approval.

## Recent News
- 2026-06-11 12:41 EST — [Chiesi Group Completes Acquisition of KalVista Pharmaceuticals](https://biopharmsignal.com/news/KALV/chiesi-group-completes-acquisition-of-kalvista-pharmaceuticals-e7f7e66b) — Source: KalVista Pharmaceuticals, Inc.
- 2026-05-28 11:00 EST — [KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-presents-new-data-highlighting-the-burden-of-injectable-on-demand-treatment-in-young-children-with-hereditary-angioedema) — Source: KalVista Pharmaceuticals, Inc.
- 2026-04-29 11:00 EST — [Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio](https://biopharmsignal.com/news/KALV/chiesi-group-to-acquire-kalvista-pharmaceuticals-expanding-its-global-rare-disease-portfolio) — Source: KalVista Pharmaceuticals, Inc.
- 2026-04-08 11:00 EST — [KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: KalVista Pharmaceuticals, Inc.
- 2026-04-02 20:01 EST — [KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: KalVista Pharmaceuticals, Inc.